Stories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
Gibraltar Industries heads into its October 28 earnings date with the stock near a one-year low, short interest at a six-week high on a monthly view, and an attention spike that suggests the market is starting to take notice.
The most compelling data point is not in the lending market. It is in the Form 4 filings. In May, CEO William Bosway bought 19,735 shares at roughly $37.44, spending close to $739,000 of his own money without a 10b5-1 plan. The CFO, Joseph Lovechio, added 1,000 shares at $34.62 that same week. The General Counsel bought in twice on the same day, adding 1,400 shares. Three executives, three separate open-market purchases, all at prices near where the stock trades today at $38.43. That cluster is meaningful because it was discretionary and because the stock has not recovered to give them a gain, it has effectively gone nowhere since they pulled the trigger.
Short interest at 6.5% of the free float is the highest it has been since early September on a monthly comparison, up about 43% over that span. Yet the lending conditions do not suggest a heated bearish conviction trade. Borrow costs are running at just 0.51%, among the lowest readings of the past 30 days, and availability is wide at 714%, meaning there are roughly seven shares available to borrow for every one already out on loan. The ORTEX short score has drifted down from 53.4 at the end of September to 50.8, moving toward neutral rather than signalling peak bearishness. The picture in the options market is quieter still. The put/call ratio has fallen sharply from the mid-40s seen throughout much of August and September to 2.17 today, closer to the 52-week low end of the range and well below the 20-day mean of 17.75. That compression in the PCR is striking and reflects a genuine shift in options positioning, though the thin options market on a small-cap building products name makes the ratio volatile.
The valuation tells a story of a stock that the market has repriced sharply lower. The price-to-earnings multiple has contracted by 2.1 points over the past month to 8.4x, and EV/EBITDA has compressed by 0.24 points to 3.2x. Both are low multiples in absolute terms, a view the EV/EBIT factor score underscores: at the 89th percentile, Gibraltar scores near the top of the universe on value by this measure. The earnings surprise factor score is, however, a flag in the other direction, sitting at the 11th percentile. The stock has a recent history of disappointing relative to expectations, and the most recent print in August saw a 5.7% one-day jump, suggesting the market was positioned for worse. Analyst coverage is thin and the most recent price target data is from August, pointing to a mean target of $75.25, which appears stale given the stock's current level. Only Longbow Research has initiated in the past year, with a Buy in July.
One piece of colour worth noting: Wikipedia views and ORTEX page traffic for Gibraltar have spiked to a z-score of 4.1 relative to the company's own 90-day history, an attention signal from the alt data layer. That is retail interest, not a revenue indicator, but it does suggest the stock's move lower has drawn eyes to it. On the institutional side, FMR raised its stake to 15% as of its May filing, and AllianceBernstein lifted its position to 7.4% by the same month. Wellington, by contrast, cut from 6.8% to 1.8% between February and August 2025, a material exit. All stakes are as last disclosed and holders below 5% may not file again.
The next test is the October 28 print. With the CEO holding shares bought at prices close to current levels and valuation multiples near multi-year lows, the debate heading into that report is less about whether the stock looks cheap and more about whether the earnings surprise factor score signals that estimates are still too high.
See the live data behind this article on ORTEX.
Open ROCK on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.
